PL2240442T3 - Sposób wytwarzania przydatny w syntezie atorwastatyny - Google Patents

Sposób wytwarzania przydatny w syntezie atorwastatyny

Info

Publication number
PL2240442T3
PL2240442T3 PL08741152T PL08741152T PL2240442T3 PL 2240442 T3 PL2240442 T3 PL 2240442T3 PL 08741152 T PL08741152 T PL 08741152T PL 08741152 T PL08741152 T PL 08741152T PL 2240442 T3 PL2240442 T3 PL 2240442T3
Authority
PL
Poland
Prior art keywords
atorvastatin
synthesis
preparation process
process useful
useful
Prior art date
Application number
PL08741152T
Other languages
English (en)
Inventor
Dong-Ock Cho
Younja Kwon
Kyeong-Hoi Cha
Yeongsook Kim
Hyun-Seop Tae
Original Assignee
Medichem Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem Korea Co Ltd filed Critical Medichem Korea Co Ltd
Publication of PL2240442T3 publication Critical patent/PL2240442T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL08741152T 2008-01-02 2008-04-04 Sposób wytwarzania przydatny w syntezie atorwastatyny PL2240442T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020080000083A KR100850558B1 (ko) 2008-01-02 2008-01-02 아토르바스타틴의 효율적인 제조방법
EP08741152A EP2240442B1 (en) 2008-01-02 2008-04-04 Preparation process useful in synthesis of atorvastatin
PCT/KR2008/001902 WO2009084773A2 (en) 2008-01-02 2008-04-04 Preparation process useful in synthesis of atorvastatin

Publications (1)

Publication Number Publication Date
PL2240442T3 true PL2240442T3 (pl) 2012-11-30

Family

ID=39881235

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08741152T PL2240442T3 (pl) 2008-01-02 2008-04-04 Sposób wytwarzania przydatny w syntezie atorwastatyny

Country Status (6)

Country Link
US (1) US8124790B2 (pl)
EP (1) EP2240442B1 (pl)
JP (1) JP2011515328A (pl)
KR (1) KR100850558B1 (pl)
PL (1) PL2240442T3 (pl)
WO (1) WO2009084773A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112851504B (zh) * 2021-02-09 2022-10-14 山东艾孚特科技有限公司 一种异丁酰乙酸甲酯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1998004543A1 (en) 1996-07-29 1998-02-05 Warner-Lambert Company Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
EP1480943A2 (en) 2002-11-15 2004-12-01 Teva Pharmaceutical Industries Limited Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
AU2004317570B2 (en) * 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CN1980890A (zh) * 2004-05-31 2007-06-13 兰贝克赛实验室有限公司 阿托伐他汀的制备方法
WO2006110918A1 (en) 2005-04-13 2006-10-19 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
ATE432276T1 (de) 2005-09-09 2009-06-15 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
KR20080000083A (ko) * 2006-06-26 2008-01-02 엘지.필립스 엘시디 주식회사 액정표시소자의 제조방법

Also Published As

Publication number Publication date
WO2009084773A2 (en) 2009-07-09
EP2240442B1 (en) 2012-06-20
WO2009084773A3 (en) 2010-02-18
US20110112309A1 (en) 2011-05-12
KR100850558B1 (ko) 2008-08-06
EP2240442A2 (en) 2010-10-20
JP2011515328A (ja) 2011-05-19
US8124790B2 (en) 2012-02-28
EP2240442A4 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
IL208328A0 (en) Methods to produce strechable products
ZA201102510B (en) Slurry process for synthesis of biophosphites
ZA201101836B (en) Process for the preparation of rufinamide
ZA200905335B (en) Process for the synthesis of agomelatine
IL208792A0 (en) Process for the preparation of amides
IL226244A (en) Methods for the synthesis of amine thiazolopyridine-2-ylaoxy-phenyl and thiazolopyrazine-2-ylaoxy-phenyl
ZA201100123B (en) Bromine-facilitated synthesis of fluoro-sulfur compounds
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
PL2279175T3 (pl) Sposób wytwarzania związków pośrednich naftalen-2-ylopirazol-3-onu użytecznych w syntezie inhibitorów receptorów sigma
GB0817926D0 (en) Articles of clothiing
EG26332A (en) Process for the preparation of benzonoprons
ZA200905051B (en) Process for the synthesis of agomelatine
GB0819537D0 (en) Method of product authentification
IL183445A0 (en) Continuous process of preparing bromopicrin
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON
IL210106A0 (en) Methods of synthesis of morphinans
IL208918A0 (en) Methods of preparing substituted heterocycles-149
EP2240442A4 (en) FOR THE SYNTHESIS OF ATORVASTATIN SUITABLE PRODUCTION PROCESS
GB0823366D0 (en) Synthesis
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
SI2504309T1 (sl) Sinteza acetokslacetaldehida
IL198572A0 (en) Process for the preparation of tigecycline in the amorphous form
IL213110A0 (en) Process for the preparation of tetrazine derivatives